eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2018
vol. 15
 
Share:
Send email
Share:
abstract:
Review paper

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years

Agnieszka Rybarczyk-Kasiuchnicz
,
Rodryg Ramlau

Kardiochirurgia i Torakochirurgia Polska 2018; 15 (2): 119-124
DOI: https://doi.org/10.5114/kitp.2018.76478
Online publish date: 2018/06/22
View full text Get citation
 
PlumX metrics:
Lung cancer is the main cause of cancer-related deaths in Poland. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a new group of agents for non-small-cell lung cancer (NSCLC) patients. Determining the predictive value of activating mutations in the EGFR and ROS-1 genes and ALK rearrangement in non-small-cell lung cancer has enabled the identification of patients likely to achieve true clinical benefits. EGFR-TKIs may produce objective response in more than 60% of patients and prolong progression-free survival to 10 months in mutation-positive patients. No improvement of overall survival was shown in randomized trials. The era of immunotherapy implementing PD-1 and PD-L1 inhibitors has changed the face of lung cancer therapy. We aimed to review the literature on the use of EGFR-TKIs and immunotherapeutic agents for NSCLC patients.
keywords:

non-small-cell lung cancer, growth factor receptor tyrosine kinase inhibitors, ALK-rearrangement, immunotherapy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.